These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 9517366)

  • 1. Characteristics of indirect pharmacodynamic models and applications to clinical drug responses.
    Sharma A; Jusko WJ
    Br J Clin Pharmacol; 1998 Mar; 45(3):229-39. PubMed ID: 9517366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologic indirect response models characterize diverse types of pharmacodynamic effects.
    Jusko WJ; Ko HC
    Clin Pharmacol Ther; 1994 Oct; 56(4):406-19. PubMed ID: 7955802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.
    Ayyar VS; Jusko WJ
    Pharmacol Rev; 2020 Apr; 72(2):414-438. PubMed ID: 32123034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moving from basic toward systems pharmacodynamic models.
    Jusko WJ
    J Pharm Sci; 2013 Sep; 102(9):2930-40. PubMed ID: 23681608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feedback control indirect response models.
    Zhang Y; D'Argenio DZ
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):343-58. PubMed ID: 27394724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. D-optimal designs for parameter estimation for indirect pharmacodynamic response models.
    Khinkis LA; Krzyzanski W; Jusko WJ; Greco WR
    J Pharmacokinet Pharmacodyn; 2009 Dec; 36(6):523-39. PubMed ID: 19904585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indirect pharmacodynamic models for responses with multicompartmental distribution or polyexponential disposition.
    Krzyzanski W; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2001 Feb; 28(1):57-78. PubMed ID: 11253614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of dosage regimen in controlling indirect pharmacodynamic responses.
    Gobburu JV; Jusko WJ
    Adv Drug Deliv Rev; 2001 Mar; 46(1-3):45-57. PubMed ID: 11259832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mathematical formalism for the properties of four basic models of indirect pharmacodynamic responses.
    Krzyzanski W; Jusko WJ
    J Pharmacokinet Biopharm; 1997 Feb; 25(1):107-23. PubMed ID: 9353696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect pharmacodynamic models for responses with circadian removal.
    Ayyar VS; Krzyzanski W; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2019 Feb; 46(1):89-101. PubMed ID: 30694437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
    Meibohm B; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic Models of Indirect Effects and Irreversible Inactivation with Turnover: Applicability to Mechanism-Based Modeling of Gene Silencing and Targeted Protein Degradation.
    Wang AF; Ayyar VS
    J Pharm Sci; 2024 Jan; 113(1):191-201. PubMed ID: 37884193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of basic indirect pharmacodynamic response models with physiological limits.
    Yao Z; Krzyzanski W; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2006 Apr; 33(2):167-93. PubMed ID: 16547797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena.
    Sharma A; Ebling WF; Jusko WJ
    J Pharm Sci; 1998 Dec; 87(12):1577-84. PubMed ID: 10189270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diversity of mechanism-based pharmacodynamic models.
    Mager DE; Wyska E; Jusko WJ
    Drug Metab Dispos; 2003 May; 31(5):510-8. PubMed ID: 12695336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approaches to pharmacokinetic/ pharmacodynamic modeling during pregnancy.
    Wyska E; Jusko WJ
    Semin Perinatol; 2001 Jun; 25(3):124-32. PubMed ID: 11453607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics.
    Minto CF; Schnider TW; Gregg KM; Henthorn TK; Shafer SL
    Anesthesiology; 2003 Aug; 99(2):324-33. PubMed ID: 12883405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of drug interactions relevant to pharmacodynamic indirect response models.
    Earp J; Krzyzanski W; Chakraborty A; Zamacona MK; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2004 Oct; 31(5):345-80. PubMed ID: 15669772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic-pharmacodynamic modelling in pre-clinical investigations: principles and perspectives.
    Danhof M; Mandema JW; Hoogerkamp A; Mathôt RA
    Eur J Drug Metab Pharmacokinet; 1993; 18(1):41-7. PubMed ID: 8335038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of pharmacodynamic recession slopes for direct and indirect response models.
    Krzyzanski W; Jusko WJ
    J Pharmacokinet Biopharm; 1998 Aug; 26(4):409-36. PubMed ID: 10214560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.